Chondroitin sulfate shows its effectiveness condroprotectora with a new method of measurement: nuclear magnetic resonance (NMR).

-A multicenter clinical trial, randomized, double-blind, placebo-controlled, carried out by the Group of Prof. Jean-Pierre Pelletier reveals new clinical evidence: patients treated with chondroitin sulfate have experienced a reduction in the loss of the volume of the cartilage in the lateral compartment of the knee against placebo

Barcelona, October 2010.- during the celebration of the annual Congress of the international society of research in osteoarthritis (OARSI) that has taken place in Brussels, the renowned Canadian rheumatologist Prof. Pelletier has presented a clinical trial carried out in five prestigious Canadian hospitals. The data show new evidence on chondroitin sulfate to measure its modifier effect on the structure of the joint artrósica through an objective technique such as Nuclear magnetic resonance (NMR).

The MRI allows to measure the effect of the condroprotectores in 6 months, 1 year and 2 years. With this study, Prof. Pelletier demonstrated that patients treated with chondroitin sulfate have experienced a reduction in the loss of volume of cartilage in the lateral compartment of the knee with placebo. Chondroitin sulfate was also able to reduce the size of the lesions of bone subcondral.

These results corroborate data published recently in the literature in other clinical trials conducted with chondroitin sulfate, such as the STOPP study [1], the clinical trial conducted by Michel and cols [2], and the meta-analysis published by Prof. Hochberg [3].

This new technique of measuring leads to existing ones, the x-rays and arthroscopy, because it is much more reliable and less harmful for the patient, as well as presenting a greater sensitivity to x-rays, given that the effect of chondroitin sulfate is seen already after the first 6 months of treatment.

The NMR confirms once again the positive effects of chondroitin sulfate in the treatment of osteoarthritis. Chondroitin sulphate acts 3 structures concerned in the process artrósico: reduces the deterioration of the cartilage, reduces the inflammation of the synovial membrane and re-equilibra metabolism of bone subcondral.

OARSI

OARSI is the first international organization of scientists and health professionals who work for the prevention and treatment of osteoarthritis through the promotion and presentation of studies, training and dissemination of new knowledge at the global level.

References

[1] Kahan to et to the. Long-Term Effects of Chondroitins 4 and 6 Sulfate on Knee Osteoarthritis. Arthritis Rheum. 2009 Feb; 58 (11): 524-533

[2] Michel B, et to the. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. A randomized, controlled trial. Arthritis Rheum 2005, 52 (3): 779-786

[3] Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010 Jun; 18 Suppl. 1:S28 – 31.